Difference between revisions of "Acute myeloid leukemia"
Line 2: | Line 2: | ||
==Induction therapy (APL, acute promyelocytic leukemia)== | ==Induction therapy (APL, acute promyelocytic leukemia)== | ||
− | ===ATRA, daunorubicin, cytarabine=== | + | ===ATRA, daunorubicin, cytarabine #1=== |
====Regimen==== | ====Regimen==== | ||
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission | ||
Line 10: | Line 10: | ||
'''7-day initial induction chemotherapy, with ongoing use of ATRA''' | '''7-day initial induction chemotherapy, with ongoing use of ATRA''' | ||
− | To be followed by [[# | + | To be followed by [[#Daunorubicin.2C_Cytarabine.2C_IT_chemo|Daunorubicin, Cytarabine, IT chemo]] consolidation therapy. |
====References==== | ====References==== | ||
− | ===ATRA, idarubicin, cytarabine | + | ===ATRA, idarubicin, cytarabine #2=== |
====Regimen==== | ====Regimen==== | ||
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission | ||
Line 21: | Line 21: | ||
'''7-day initial induction chemotherapy, with ongoing use of ATRA''' | '''7-day initial induction chemotherapy, with ongoing use of ATRA''' | ||
+ | |||
+ | To be followed by [[#Arsenic.2C_ATRA.2C_Daunorubicin|Arsenic, ATRA, Daunorubicin]] consolidation therapy. | ||
====References==== | ====References==== | ||
Line 33: | Line 35: | ||
'''8-day initial induction chemotherapy, with ongoing use of ATRA''' | '''8-day initial induction chemotherapy, with ongoing use of ATRA''' | ||
+ | |||
+ | To be followed by [[http://hemonc.org/Acute_myeloid_leukemia#AIDA_-_consolidation_therapy|AIDA consolidation therapy]] or [[ATRA.2C_idarubicin.2C_cytarabine.2C_mitoxantrone|ATRA, idarubicin, cytarabine, mitoxantrone]] consolidation therapy. | ||
====References==== | ====References==== | ||
Line 64: | Line 68: | ||
====References==== | ====References==== | ||
− | ===Arsenic, ATRA, | + | ===Arsenic, ATRA, Daunorubicin=== |
====Regimen==== | ====Regimen==== | ||
*[[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV days 1-5, 8-12, 15-19, 22-26, 29-33 | *[[Arsenic trioxide (Trisenox)]] 0.15 mg/kg IV days 1-5, 8-12, 15-19, 22-26, 29-33 | ||
Line 96: | Line 100: | ||
'''5-day course of therapy''' | '''5-day course of therapy''' | ||
+ | |||
+ | To be followed by [[#AIDA_-_maintenance_.231.2C_ATRA|ATRA]] or [[#AIDA_-_maintenance_.231.2C_ATRA|Mercaptopurine, Methotrexate, alternating with ATRA]] maintenance therapy. | ||
====References==== | ====References==== | ||
Line 105: | Line 111: | ||
====Regimen==== | ====Regimen==== | ||
*[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, days 1-15 | *[[All-trans retinoic acid (ATRA)]] 45 mg/m2/day, divided into two equal doses PO BID, days 1-15 | ||
− | *[[Idarubicin (Idamycin)]] 5 mg/m2 IV days 1-4 | + | *[[Idarubicin (Idamycin)]] 5-7 mg/m2 IV days 1-4 -- 5 mg/m2 dosage used for low risk patients, 7 mg/m2 dosage used for intermediate risk patients |
*[[Cytarabine (Cytosar)]] 1000 mg/m2 IV days 1-4 | *[[Cytarabine (Cytosar)]] 1000 mg/m2 IV days 1-4 | ||
Line 120: | Line 126: | ||
'''15-day cycle''' | '''15-day cycle''' | ||
+ | |||
+ | To be followed by [[#ATRA|ATRA]] or [[#AIDA_-_maintenance_.231.2C_ATRA|Mercaptopurine, Methotrexate, alternating with ATRA]] maintenance therapy. | ||
====References==== | ====References==== | ||
Line 127: | Line 135: | ||
==Maintenance therapy (APL, acute promyelocytic leukemia)== | ==Maintenance therapy (APL, acute promyelocytic leukemia)== | ||
− | === | + | ===ATRA=== |
AIDA: '''<u>A</u>'''TRA, '''<u>IDA</u>'''rubicin | AIDA: '''<u>A</u>'''TRA, '''<u>IDA</u>'''rubicin | ||
Line 140: | Line 148: | ||
# Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. [http://bloodjournal.hematologylibrary.org/content/117/18/4716.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21385856 PubMed] | # Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. [http://bloodjournal.hematologylibrary.org/content/117/18/4716.long link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21385856 PubMed] | ||
− | === | + | ===Mercaptopurine, Methotrexate, alternating with ATRA=== |
AIDA: '''<u>A</u>'''TRA, '''<u>IDA</u>'''rubicin | AIDA: '''<u>A</u>'''TRA, '''<u>IDA</u>'''rubicin | ||
Revision as of 21:44, 20 February 2012
Induction therapy (APL, acute promyelocytic leukemia)
ATRA, daunorubicin, cytarabine #1
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission
- Daunorubicin (Cerubidine) 60 mg/m2 IV days 1-3
- Cytarabine (Cytosar) 200 mg/m2 IV days 1-7
7-day initial induction chemotherapy, with ongoing use of ATRA
To be followed by Daunorubicin, Cytarabine, IT chemo consolidation therapy.
References
ATRA, idarubicin, cytarabine #2
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission
- Daunorubicin (Cerubidine) 50 mg/m2 IV days 1-4
- Cytarabine (Cytosar) 200 mg/m2 IV days 1-7
7-day initial induction chemotherapy, with ongoing use of ATRA
To be followed by Arsenic, ATRA, Daunorubicin consolidation therapy.
References
AIDA
AIDA: ATRA, IDArubicin
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission or maximum of 90 days.
- For patients <20 years old, All-trans retinoic acid (ATRA) dose was 25 mg/m2/day, divided into two equal doses PO BID
- Idarubicin (Idamycin) 12 mg/m2 IV days 2, 4, 6, 8
8-day initial induction chemotherapy, with ongoing use of ATRA
To be followed by [consolidation therapy] or ATRA, idarubicin, cytarabine, mitoxantrone consolidation therapy.
References
- Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F; GIMEMA Acute Leukaemia Working Party. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011 Sep;154(5):564-8. doi: 10.1111/j.1365-2141.2011.08593.x. Epub 2011 Jul 14. link to full article contains protocol PubMed
- Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains protocol PubMed
ATRA & arsenic
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting day 1 and continuing until remission
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV daily, starting day 1 and continuing until remission
References
Induction therapy (AML, acute myeloid leukemia)
Consolidation therapy (APL, acute promyelocytic leukemia)
Daunorubicin, Cytarabine, IT chemo
Regimen
- Daunorubicin (Cerubidine) 60 mg/m2 IV on days 1-3
- Cytarabine (Cytosar) 200 mg/m2 IV on days 1-7
7 days of therapy, THEN
- Daunorubicin (Cerubidine) 45 mg/m2 IV on days 1-3
- Cytarabine (Cytosar) 1500-2000 mg/m2 IV every 12 hours on days 1-7
- 5 doses of intrathecal chemotherapy
7 days of therapy
References
Arsenic, ATRA, Daunorubicin
Regimen
- Arsenic trioxide (Trisenox) 0.15 mg/kg IV days 1-5, 8-12, 15-19, 22-26, 29-33
5-week cycles x 2 cycles, THEN
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, starting days 1-7
- Daunorubicin (Cerubidine) 50 mg/m2 IV days 1-3
7-day cycles x 2 cycles
References
AIDA - consolidation therapy
AIDA: ATRA, IDArubicin
Regimen
- Idarubicin (Idamycin) 5 mg/m2 IV days 1-4 (administered second, 3 hours after cytarabine infusion complete)
- Cytarabine (Cytosar) 1000 mg/m2 IV over 6 hours on days 1-4 (administered first)
4-day course of therapy, THEN
- Mitoxantrone (Novantrone) 10 mg/m2 IV days 1-5 (administered first)
- Etoposide (Vepesid) 100 mg/m2 IV over 45-60 minutes (administered second, 12 hours after start of mitoxantrone) days 1-5
5-day course of therapy, THEN
- Idarubicin (Idamycin) 12 mg/m2 IV day 1
- Cytarabine (Cytosar) 150 mg/m2 IV every 8 hours (450 mg/m2/day total dosage) days 1-5
- Thioguanine (Tabloid) 70 mg/m2 PO every 8 hours (210 mg/m2/day total dosage) days 1-5
5-day course of therapy
To be followed by ATRA or Mercaptopurine, Methotrexate, alternating with ATRA maintenance therapy.
References
- Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002 Nov 1;100(9):3141-6. link to original article contains protocol PubMed
- Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F; GIMEMA Acute Leukaemia Working Party. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011 Sep;154(5):564-8. doi: 10.1111/j.1365-2141.2011.08593.x. Epub 2011 Jul 14. link to full article contains protocol PubMed
- Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains protocol PubMed
ATRA, idarubicin, cytarabine, mitoxantrone
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1-15
- Idarubicin (Idamycin) 5-7 mg/m2 IV days 1-4 -- 5 mg/m2 dosage used for low risk patients, 7 mg/m2 dosage used for intermediate risk patients
- Cytarabine (Cytosar) 1000 mg/m2 IV days 1-4
15-day cycle, THEN
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1-15
- Mitoxantrone (Novantrone) 10 mg/m2 IV days 1-5
15-day cycle, THEN
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID, days 1-15
- Idarubicin (Idamycin) 12 mg/m2 IV day 1
- Cytarabine (Cytosar) 450 mg/m2, divided into three equal doses IV every 8 hours, days 1-4
15-day cycle
To be followed by ATRA or Mercaptopurine, Methotrexate, alternating with ATRA maintenance therapy.
References
Consolidation therapy (AML, acute myeloid leukemia)
Maintenance therapy (APL, acute promyelocytic leukemia)
ATRA
AIDA: ATRA, IDArubicin
Regimen
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID on days 1-15
3-month cycles x 2 years (8 total cycles)
References
- Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002 Nov 1;100(9):3141-6. link to original article contains protocol PubMed
- Latagliata R, Breccia M, Fazi P, Vignetti M, Di Raimondo F, Sborgia M, Vincelli D, Candoni A, Salvi F, Rupoli S, Martinelli G, Kropp MG, Tonso A, Venditti A, Melillo L, Cimino G, Petti MC, Avvisati G, Lo-Coco F, Mandelli F; GIMEMA Acute Leukaemia Working Party. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. Br J Haematol. 2011 Sep;154(5):564-8. doi: 10.1111/j.1365-2141.2011.08593.x. Epub 2011 Jul 14. link to full article contains protocol PubMed
- Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains protocol PubMed
Mercaptopurine, Methotrexate, alternating with ATRA
AIDA: ATRA, IDArubicin
Regimen
Part A:
- Mercaptopurine (Purinethol) 1 mg/kg PO daily
- Methotrexate (MTX) 15 mg/m2 OR 0.25 mg/kg IM weekly -- papers below list different dosages
90-day course of therapy, THEN
Part B:
- All-trans retinoic acid (ATRA) 45 mg/m2/day, divided into two equal doses PO BID on days 1-15
15-day course of therapy. Alternate between Part A and Part B for a total of 2 years
References
- Avvisati G, Petti MC, Lo-Coco F, Vegna ML, Amadori S, Baccarani M, Cantore N, Di Bona E, Ferrara F, Fioritoni G, Gallo E, Invernizzi R, Lazzarino M, Liso V, Mariani G, Ricciuti F, Selleri C, Sica S, Veneri D, Mandelli F; GIMEMA (Gruppo Italiano Malattie Ematologische dell'Adulto) Italian Cooperative Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood. 2002 Nov 1;100(9):3141-6. link to original article contains protocol PubMed
- Avvisati G, Lo-Coco F, Paoloni FP, Petti MC, Diverio D, Vignetti M, Latagliata R, Specchia G, Baccarani M, Di Bona E, Fioritoni G, Marmont F, Rambaldi A, Di Raimondo F, Kropp MG, Pizzolo G, Pogliani EM, Rossi G, Cantore N, Nobile F, Gabbas A, Ferrara F, Fazi P, Amadori S, Mandelli F; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25. Epub 2011 Mar 8. link to original article contains protocol PubMed